BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36370934)

  • 1. Chronic Treatment with the Probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium lactis BB12 Attenuates Motor Impairment, Striatal Microglial Activation, and Dopaminergic Loss in Rats with 6-Hydroxydopamine-induced Hemiparkinsonism.
    Cuevas-Carbonell SG; Vásquez-Celaya L; García-López D; Granados-Patrón D; García-Miss MDR; Álvarez-Cervera FJ; Mut-Martín M; Parra I; Mendieta L; Salgado H; Alamilla J; Cruz-Bojórquez R; Ávila-Escalante ML; Aranda-González II; Góngora-Alfaro JL
    Neuroscience; 2022 Dec; 507():79-98. PubMed ID: 36370934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic feeding with 3% dried raw blueberries (V. corymbosum) reduces apomorphine-induced rotations and striatal dopaminergic loss in hemiparkinsonian rats.
    Parra-Paz VG; Calderón-Sauri A; Granados-Patrón D; Cuevas-Carbonell SG; García-López D; Dawn-Ojeda A; Mut-Martín M; Olivera-Castillo L; Álvarez-Cervera FJ; Salgado H; Alamilla J; García-Miss MDR; Vásquez-Celaya L; Aranda-González II; Góngora-Alfaro JL
    Food Res Int; 2021 Feb; 140():110066. PubMed ID: 33648289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective and Immunomodulatory Effects of Probiotics in a Rat Model of Parkinson's Disease.
    Parra I; Martínez I; Vásquez-Celaya L; Gongora-Alfaro JL; Tizabi Y; Mendieta L
    Neurotox Res; 2023 Apr; 41(2):187-200. PubMed ID: 36662412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Sleeman IJ; Boshoff EL; Duty S
    Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine.
    Rodrigues RW; Gomide VC; Chadi G
    Int J Neurosci; 2001 Jul; 109(1-2):91-126. PubMed ID: 11699344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
    Matsuura K; Makino H; Ogawa N
    Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice.
    Cui J; Zhao D; Xu M; Li Z; Qian J; Song N; Wang J; Xie J
    Sci Rep; 2024 Feb; 14(1):3721. PubMed ID: 38355892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
    Salvatore MF
    J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
    Silva C; Fuxe K; Chadi G
    J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Effects of LPS and 6-OHDA on Microglia's Morphology in Rats: Implications for Inflammatory Model of Parkinson's Disease.
    Parra I; Martínez I; Ramírez-García G; Tizabi Y; Mendieta L
    Neurotox Res; 2020 Jan; 37(1):1-11. PubMed ID: 31478124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.
    Carman LS; Gage FH; Shults CW
    Brain Res; 1991 Jul; 553(2):275-83. PubMed ID: 1681983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal application of kisspeptin-54 mitigates motor deficits by reducing nigrostriatal dopamine loss in hemiparkinsonian rats.
    Sinen O; Sinen AG; Derin N; Aslan MA
    Behav Brain Res; 2024 Jun; 468():115035. PubMed ID: 38703793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
    Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model.
    Miyanishi K; Choudhury ME; Watanabe M; Kubo M; Nomoto M; Yano H; Tanaka J
    Neurochem Int; 2019 Jan; 122():38-46. PubMed ID: 30419255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
    Gui ZH; Liu J; Wang Y; Ali U; Wang T; Chen L
    Chin J Physiol; 2011 Apr; 54(2):96-104. PubMed ID: 21789890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.